Global Cell and Gene Therapy Drug Delivery Devices Market - GLOBAL:2021

Market Report Coverage :
Start Year : 2019 - Forecast Year : 2030 - Start Value : $55.75 Thousand in 2019 - Forecast Value : $375.13 Thousand by 2030 - CAGR % : 0.17%
Description :
Market Report Coverage - Cell and Gene Therapy Drug Delivery DevicesMarket Segmentation• Product Type – Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe (1.0 ml, and 0.5 ml), Prefilled Syringe (1.0 ml, and 4.0 ml), and Infusion Bags (10 ml to 50 ml, 68 ml, 60 ml, and up to 65 ml).• Commercialized Drugs – Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, and StrimvelisRegional Segmentation• North America – U.S., Canada• Europe – Germany, France, Italy, U.K., Spain, Netherlands, Russia, and Rest-of-Europe• Asia-Pacific – China, Japan, India, South Korea, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)• Latin America – Brazil, Mexico, and Rest-of-the-Latin America• Rest-of-the-WorldGrowth Drivers• Increasing Prevalence of Cancer and Chronic Diseases• Increased Funding in Cell and Gene Therapy Market• Rising Number of the FDA Approvals of Cell and Gene Therapies & Clinical TrialsMarket Challenges• Stringent Government Regulations• Injuries and Infections Caused by NeedlesMarket Opportunities• Strong Pipeline and Drug Approvals of Cell and Gene TherapiesKey Companies ProfiledAmgen, Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio, Inc., Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd (ViroMed Co., Ltd), Human Stem Cell Institute, Kite Pharma, Inc., Kolon Tissue Gene, inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., and Vericel CorporationKey Questions Answered in this Report:• What are cell and gene therapy drug delivery devices?• What is the list of commercialized cell and gene therapies available in the market?• How did the cell and gene therapy drug delivery devices market evolve, and what is its scope in the future?• What are the major market drivers, challenges and opportunities in the global cell and gene therapy drug delivery devices market?• What are the key developmental strategies that are being implemented by the key players to sustain in this market?• How did the emerging technology landscape of cell and gene therapy drug delivery devices look like? • What will be the impact of COVID-19 on this market?• What will be the impact of COVID-19 on cell and gene therapy drug delivery devices companies?• What will be the impact of COVID-19 on supply chain of cell and gene therapy drug delivery devices market?• What are the guidelines implemented by different government bodies to regulate the approval of cell and gene therapy drug delivery devices market? • How the investments by government organizations will affect the global cell and gene therapy drug delivery devices market? • What was the market size of the leading segments and sub-segments of the global cell and gene therapy drug delivery devices market in 2019?• How will the industry evolve during the forecast period 2020- 2030?• What will be the growth rate of the cell and gene therapy drug delivery devices market during the forecast period?• How will each of the segments of the global cell and gene therapy drug delivery devices market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2030?• Which product segment, and commercialized drug segment is expected to register the highest CAGR for the cell and gene therapy drug delivery devices market?• What is the market size of cell and gene therapy drug delivery devices market in different countries of the world?• Which geographical region will contribute to the highest sales of cell and gene therapy drug delivery devices market?• What are the reimbursement scenario and regulatory structure for the cell and gene therapy drug delivery devices in different regions?• What are the key strategies incorporated by the players of global cell and gene therapy drug delivery devices market, to sustain the competition and retain their supremacy?Market OverviewCell and gene therapy drug delivery industry is a transformative industry whose full potential is only just beginning to emerge. Cell and gene therapy involves the extraction of cells, protein, or genetic material (DNA) from the donor, and altering them to provide highly personalized therapy. Cell and gene therapies may offer longer-lasting effects than traditional medicines. One of the significant drugs of the cell and gene therapy industry is CAR-T cell-based medicines, which include both cell therapy and gene therapy. Various market players are actively investing in the research and development of the cell and gene therapy industry. The players are offering improved and new products, which meet the critical needs of patients. The global cell and gene therapy drug delivery devices market was valued at $55.75 thousand in 2019, and is expected to reach $375.13 thousand by 2030, registering a CAGR of 16.61% during the forecast.The growth is attributed to major drivers in this market such as increasing prevalence of cancer and chronic diseases, increased funding in cell and gene therapy market, rising need to develop novel treatment options for rare disease, and rising biopharmaceutical R&D expenditure, and rising number of the FDA approvals of cell and gene therapies & clinical trials. The market is expected to grow at a significant growth rate due to various potential opportunities of growth that lie within its domain, which include drug approvals and strong pipeline of cell and gene therapies.Various new cell and gene-based therapy approaches use biological engineering to improve the immune system’s capacity to fight disease while sparing healthy tissues in the body. For instance, there are antibody-based therapies that can make T-cells more effective by increasing their interactions with cancer cells. Other modifications, such as adding complexity to the CAR-T and cancer cell interaction, which can further sharpen T-cells’ cancer-targeting ability by reducing damage to normal cells. The increase in geriatric population and increasing number of cancer cases, and genetic disorders across the globe are expected to translate into a significantly higher demand for cell and gene therapy drug delivery devices market.Furthermore, the companies are investing huge amount in research and development of cell and gene therapies and associated drug delivery devices products. The clinical trial landscape of various genetic and chronic diseases has been on the rise in the recent years, this will fuel the cell and gene therapy drug delivery devices market in future.Within the research report, the market is segmented based on product type, commercialized drugs, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel cell and gene therapy drug delivery devices. Due to the diverse product portfolio and intense market penetration, Novartis AG, Kite Pharma Inc., and Dendreon Pharmaceuticals LLC. have been the pioneers in this field and been the major competitors in this market. The other major contributors of the market include companies such as Vericel Corporation, Amgen Inc., Bausch & Lomb Incorporated, Spark Therapeutics, Inc., and Becton, Dickinson and Company.Based on region, North America holds the largest share of cell and gene therapy drug delivery devices market due to substantial investments made by biotechnology and pharmaceutical companies, improved healthcare infrastructure, rise in per capita income, early availability of approved therapies, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.
Countries Covered :
North America U.S. CanadaEurope Germany Italy France Spain Netherlands U.K. Russia Rest-of-EuropeAsia-Pacific China India Australia South Korea Japan Singapore Rest-of-Asia-PacificLatin America Brazil Mexico Rest-of-Latin AmericaRest-of-World
Keywords :
Cell and Gene Therapy Drug Delivery Devices Market, Cell Therapy Drug Delivery Devices, Gene Therapy Drug Delivery Devices, Cell and Gene Therapy Drug Delivery Devices, Cell and Gene Therapy Drug Delivery Devices Market, Cell and Gene Therapy Drug Delivery Devices Industry, Cell and Gene Therapy Drug Delivery Devices Report, Cell and Gene Therapy Drug Delivery Devices Market Forecasts, Cell and Gene Therapy Drug Delivery Devices Market Trends, Cell and Gene Therapy Drug Delivery Devices Market Products, Cell and Gene Therapy Drug Delivery Devices Market Applications, Cell and Gene Therapy Drug Delivery Devices Market Companies, Cell and Gene Therapy Drug Delivery Devices Market Analysis, Cell and Gene Therapy Drug Delivery Devices Industry Analysis, What are Cell and Gene Therapy Drug Delivery Devices, Cell and Gene Therapy Drug Delivery Devices Definition, Subretinal Injection Cannula Cell and Gene Therapy Drug Delivery Devices Market, Extension Tube Cell and Gene Therapy Drug Delivery Devices Market, Intravenous Catheter Cell and Gene Therapy Drug Delivery Devices Market, Sterile Insulin Syringe Cell and Gene Therapy Drug Delivery Devices Market, Pre-Filled Syringe Cell and Gene Therapy Drug Delivery Devices Market, Infusion Bags Cell and Gene Therapy Drug Delivery Devices Market, Luxturna Cell and Gene Therapy Drug Delivery Devices Market, Kymriah Cell and Gene Therapy Drug Delivery Devices Market, Provenge Cell and Gene Therapy Drug Delivery Devices Market, Zolgensma Cell and Gene Therapy Drug Delivery Devices Market, Yescarta Cell and Gene Therapy Drug Delivery Devices Market, Strimvelis Cell and Gene Therapy Drug Delivery Devices Market, North America Cell and Gene Therapy Drug Delivery Devices Market, Europe Cell and Gene Therapy Drug Delivery Devices Market, Asia-Pacific Cell and Gene Therapy Drug Delivery Devices Market, Latin America Cell and Gene Therapy Drug Delivery Devices Market
Press Release :
The global cell and gene therapy drug delivery devices market is projected to reach $375.13 thousand by 2030, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 16.61% during the period between 2020 and 2030.The comprehensive study of global cell and gene therapy drug delivery devices market BIS Research extensively covers the following:• Market numbers on micro-segments that are influencing the market • Currently over 15 products present in the market• Clinical trial data for over 30 clinical trials • Pricing data for over 15 products• Evaluation of over 20 brands• Market share analysis• End-user preference data• Detailed global and regional market share analysis including the scrutiny of more than 15 countries • Study of data of more than 20 companiesBesides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, and segmental analysis. BIS Research study indicates that the increasing global geriatric population, prevalence of genetic disorders, the increased demand for gene therapeutics that not only cure the chronic conditions completely but also improve the quality of life of the patients are the major factors anticipated to contribute to the growth of the global cell and gene therapy drug delivery devices market.The study highlights the various emerging opportunities, such as strong pipeline and drug approvals of cell and gene therapies, introduction of cell and gene therapy drug delivery devices, potential technologies in cell and gene therapy drug delivery devices market, original equipment manufacturers, clinical trial scenario, and approved cell and gene therapy drug delivery devices. Scope of cell and gene therapy drug delivery devices, the clinical trial landscape of cell and gene therapies in China, the U.S, and across the world, challenges in cell and gene therapy drug delivery devices, and massive scope for adoption of cell and gene therapy drug delivery devices in emerging nations that can be leveraged by players operating in the market.Data from different segments of the market has been analyzed minutely to gain a holistic view of the market. These segments include market by product type, commercialized drugs, and regions. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study. To emphasize the dominance of the intravenous catheter segment of cell and gene therapy drug delivery devices market by product segment over other segments under the product category of cell and gene therapy drug delivery devices market in 2020 and 2030, Raviteja Palakurthy, Senior Research Analyst – BIS Research, states, "The reason for market growth and the dominance of intravenous catheter segment can be attributed to the increasing global usage of intravenous catheters to deliver drugs that are dosed frequently for fairly long periods of time and for specific disease conditions. For most of currently approved cell and gene therapies such as Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis, Zynteglo, and Tecartus intravenous catheter are used as its drug delivery device”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 20 leading companies, market participants, and vendors. The key players profiled in the report include Amgen, Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio, Inc., Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd (ViroMed Co., Ltd), Human Stem Cell Institute, Kite Pharma, Inc., Kolon Tissue Gene, inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., and Vericel Corporation. The study also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Who should buy this report?• Manufacturers of Cell and Gene Therapy Drug Delivery Devices • Distributors of Cell and Gene Therapy Drug Delivery Devices• Suppliers of Cell and Gene Therapy Drug Delivery Devices• CROs of Cell and Gene Therapy Drug Delivery Devices• Research and Academic InstitutionsHow can market intelligence on Cell and Gene Therapy Drug Delivery Devices add value to an organization’s decision-making process?• Aids in product development • Aids in analyzing the pipeline of products• Helps in targeting a segment for launching a new product • Offers go to market strategies for the different product categories• Supports in diversifying the product portfolio based on unmet needs• Helps in analyzing technological substitutes and compare the specification• Helps in understanding the clinical trial landscape• Helps to adjust the pricing of upcoming products• Assists in exploring the newer applications• Supports in analyzing the competitors’ funding scenarioInsightful Questions Covered to Enable Companies Take Strategic Decisions• What are cell and gene therapy drug delivery devices?• What is the list of commercialized cell and gene therapies available in the market?• How did the cell and gene therapy drug delivery devices market evolve, and what is its scope in the future?• What are the major market drivers, challenges and opportunities in the global cell and gene therapy drug delivery devices market?• What are the key developmental strategies that are being implemented by the key players to sustain in this market?• How did the emerging technology landscape of cell and gene therapy drug delivery devices look like? • What will be the impact of COVID-19 on this market?• What will be the impact of COVID-19 on cell and gene therapy drug delivery devices companies?• What will be the impact of COVID-19 on supply chain of cell and gene therapy drug delivery devices market?• What are the guidelines implemented by different government bodies to regulate the approval of cell and gene therapy drug delivery devices market? • How the investments by government organizations will affect the global cell and gene therapy drug delivery devices market? • What was the market size of the leading segments and sub-segments of the global cell and gene therapy drug delivery devices market in 2019?• How will the industry evolve during the forecast period 2020- 2030?• What will be the growth rate of the cell and gene therapy drug delivery devices market during the forecast period?• How will each of the segments of the global cell and gene therapy drug delivery devices market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2030?• Which product segment, and commercialized drug segment is expected to register the highest CAGR for the cell and gene therapy drug delivery devices market?• What is the market size of cell and gene therapy drug delivery devices market in different countries of the world?• Which geographical region will contribute to the highest sales of cell and gene therapy drug delivery devices market?• What are the reimbursement scenario and regulatory structure for the cell and gene therapy drug delivery devices in different regions?• What are the key strategies incorporated by the players of global cell and gene therapy drug delivery devices market, to sustain the competition and retain their supremacy?
Companies Mentioned :
Amgen Inc.Bausch & Lomb IncorporatedBecton, Dickinson and CompanyBluebird bio, Inc.Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)Dendreon Pharmaceuticals LLCHelixmith Co., Ltd (ViroMed Co., Ltd)Human Stem Cells InstituteKite Pharma, Inc.Kolon TissueGene, Inc.Novartis AGOrchard Therapeutics plc.Pfizer, Inc.Renova TherapeuticsSpark Therapeutics, Inc.uniQure N.V.Vericel Corporation
Press Release :
The global cell and gene therapy drug delivery devices market is projected to reach $375.13 thousand by 2030, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 16.61% during the period between 2020 and 2030.The comprehensive study of global cell and gene therapy drug delivery devices market BIS Research extensively covers the following:• Market numbers on micro-segments that are influencing the market • Currently over 15 products present in the market• Clinical trial data for over 30 clinical trials • Pricing data for over 15 products• Evaluation of over 20 brands• Market share analysis• End-user preference data• Detailed global and regional market share analysis including the scrutiny of more than 15 countries • Study of data of more than 20 companiesBesides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, and segmental analysis. BIS Research study indicates that the increasing global geriatric population, prevalence of genetic disorders, the increased demand for gene therapeutics that not only cure the chronic conditions completely but also improve the quality of life of the patients are the major factors anticipated to contribute to the growth of the global cell and gene therapy drug delivery devices market.The study highlights the various emerging opportunities, such as strong pipeline and drug approvals of cell and gene therapies, introduction of cell and gene therapy drug delivery devices, potential technologies in cell and gene therapy drug delivery devices market, original equipment manufacturers, clinical trial scenario, and approved cell and gene therapy drug delivery devices. Scope of cell and gene therapy drug delivery devices, the clinical trial landscape of cell and gene therapies in China, the U.S, and across the world, challenges in cell and gene therapy drug delivery devices, and massive scope for adoption of cell and gene therapy drug delivery devices in emerging nations that can be leveraged by players operating in the market.Data from different segments of the market has been analyzed minutely to gain a holistic view of the market. These segments include market by product type, commercialized drugs, and regions. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study. To emphasize the dominance of the intravenous catheter segment of cell and gene therapy drug delivery devices market by product segment over other segments under the product category of cell and gene therapy drug delivery devices market in 2020 and 2030, Raviteja Palakurthy, Senior Research Analyst – BIS Research, states, "The reason for market growth and the dominance of intravenous catheter segment can be attributed to the increasing global usage of intravenous catheters to deliver drugs that are dosed frequently for fairly long periods of time and for specific disease conditions. For most of currently approved cell and gene therapies such as Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis, Zynteglo, and Tecartus intravenous catheter are used as its drug delivery device”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 20 leading companies, market participants, and vendors. The key players profiled in the report include Amgen, Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio, Inc., Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd (ViroMed Co., Ltd), Human Stem Cell Institute, Kite Pharma, Inc., Kolon Tissue Gene, inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., and Vericel Corporation. The study also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Who should buy this report?• Manufacturers of Cell and Gene Therapy Drug Delivery Devices • Distributors of Cell and Gene Therapy Drug Delivery Devices• Suppliers of Cell and Gene Therapy Drug Delivery Devices• CROs of Cell and Gene Therapy Drug Delivery Devices• Research and Academic InstitutionsHow can market intelligence on Cell and Gene Therapy Drug Delivery Devices add value to an organization’s decision-making process?• Aids in product development • Aids in analyzing the pipeline of products• Helps in targeting a segment for launching a new product • Offers go to market strategies for the different product categories• Supports in diversifying the product portfolio based on unmet needs• Helps in analyzing technological substitutes and compare the specification• Helps in understanding the clinical trial landscape• Helps to adjust the pricing of upcoming products• Assists in exploring the newer applications• Supports in analyzing the competitors’ funding scenarioInsightful Questions Covered to Enable Companies Take Strategic Decisions• What are cell and gene therapy drug delivery devices?• What is the list of commercialized cell and gene therapies available in the market?• How did the cell and gene therapy drug delivery devices market evolve, and what is its scope in the future?• What are the major market drivers, challenges and opportunities in the global cell and gene therapy drug delivery devices market?• What are the key developmental strategies that are being implemented by the key players to sustain in this market?• How did the emerging technology landscape of cell and gene therapy drug delivery devices look like? • What will be the impact of COVID-19 on this market?• What will be the impact of COVID-19 on cell and gene therapy drug delivery devices companies?• What will be the impact of COVID-19 on supply chain of cell and gene therapy drug delivery devices market?• What are the guidelines implemented by different government bodies to regulate the approval of cell and gene therapy drug delivery devices market? • How the investments by government organizations will affect the global cell and gene therapy drug delivery devices market? • What was the market size of the leading segments and sub-segments of the global cell and gene therapy drug delivery devices market in 2019?• How will the industry evolve during the forecast period 2020- 2030?• What will be the growth rate of the cell and gene therapy drug delivery devices market during the forecast period?• How will each of the segments of the global cell and gene therapy drug delivery devices market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2030?• Which product segment, and commercialized drug segment is expected to register the highest CAGR for the cell and gene therapy drug delivery devices market?• What is the market size of cell and gene therapy drug delivery devices market in different countries of the world?• Which geographical region will contribute to the highest sales of cell and gene therapy drug delivery devices market?• What are the reimbursement scenario and regulatory structure for the cell and gene therapy drug delivery devices in different regions?• What are the key strategies incorporated by the players of global cell and gene therapy drug delivery devices market, to sustain the competition and retain their supremacy?
Headline :
Global Cell and Gene Therapy Drug Delivery Devices Market to Reach $375.13 Thousand by 2030
Table of Contents :
Executive Summary 1 Technology Definition1.1 Inclusion and Exclusion Criteria1.1.1 Inclusions1.1.2 Exclusions2 Research Scope3 Key Questions Answered in the Report4 Research Methodology4.1 Cell and Gene Therapy Drug Delivery Devices: Research Methodology4.2 Primary Data Sources4.3 Secondary Data Sources4.4 Market Estimation Model4.5 Criteria for Company Profiling5 Market Overview5.1 Introduction5.2 Cell and Gene Therapies and Drug Delivery Devices Industry5.3 Cell and Gene Therapy Drugs and Their Clinical Importance5.4 Cell and Gene Therapy Drug Delivery Devices Market: Current Scenario5.5 Cell and Gene Therapy Drug Delivery Devices Market: Future Perspective6 Global Cell and Gene Therapy Drug Delivery Devices Market and Growth Potential, 2020-20306.1 Overview6.2 Pipeline Analysis6.2.1 Drug Delivery Systems in Development: Current Scenario6.2.1.1 Ongoing Clinical Trials of Drug Delivery Systems6.2.1.2 Limitations of Cell and Gene Therapy Drug Delivery Devices6.2.1.3 Recent Advancements in Gene Therapy Drug Delivery6.3 Cell and Gene Therapy Drug Delivery Devices Market and Growth Potential6.4 Cell and Gene Therapy Drug Development and Commercialization Landscape6.5 Impact of COVID-19 on Cell and Gene Therapy Drug Delivery Devices Market6.5.1 Impact of COVID-19 on Global Cell and Gene Therapy Drug Delivery Devices Market Growth Rate6.5.2 Impact of COVID-19 on Supply Chain of Cell and Gene Therapy Drug Delivery Devices Market6.5.3 Clinical Trial Disruptions and Resumptions7 Emerging Technology Landscape7.1 Potential Technologies in Cell and Gene Therapy Drug Delivery Devices Market7.2 Microchip Technology7.3 Nanotechnology-Based Drug Delivery Devices7.4 Lipid Nanoparticles in Gene Therapy8 Market Dynamics8.1 Impact Analysis8.2 Market Drivers8.2.1 Increasing Prevalence of Cancer and Chronic Diseases8.2.2 Increased Funding of Cell and Gene Therapies8.2.3 Rising Number of FDA Approvals of Cell and Gene Therapies, and Clinical Trials8.3 Market Restraints8.3.1 Stringent Legal Requirements and Regulations8.3.2 Injuries and Infections Caused by Needles8.4 Market Opportunities8.4.1 Strong Pipeline of Cell and Gene Therapies9 Industry Insights9.1 Regulatory Scenario of Cell and Gene Therapy Drug Delivery Devices Market9.1.1 Overview9.1.2 Risk Assessment of Medical Devices9.1.3 Regulation of Medical Devices in the U.S.9.1.3.1 Food and Drug Administration (FDA)9.1.3.2 Food and Drug Administration (FDA) Regulations Modification9.1.4 Regulation of Medical Devices in Europe9.1.4.1 Regulations in Europe – Highlights9.1.4.2 EU Regulatory Pathway for Medical Device9.1.4.3 Federal Agencies of EU Member States9.1.4.4 European Commission Regulations Modification9.1.5 Regulation of Medical Devices in Asia-Pacific9.1.5.1 Overview9.1.5.2 Regulatory and Market Access Challenges in Asia-Pacific9.1.5.3 Regulatory Environment for Medical Devices in China9.2 Pricing and Reimbursement of Cell and Gene Therapy Drug Delivery Devices10 Patent Landscape11 Global Cell and Gene Therapy Drug Delivery Devices Market (by Product Type)11.1 Overview11.2 Subretinal Injection Cannula11.3 Extension Tube11.4 Intravenous Catheter11.5 Sterile Insulin Syringe11.5.1 Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle)11.5.2 Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle)11.6 Pre-Filled Syringe11.6.1 Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle)11.6.2 Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle)11.7 Infusion Bags11.7.1 Infusion Bags (Size 10 ML to 50 ML)11.7.2 Infusion Bags (Size 68 ML)11.7.3 Infusion Bags (Size 60 ML)11.7.4 Infusion Bags (Size Up to 65 ML)12 Global Cell and Gene Therapy Drug Delivery Devices Market (by Commercialized Drugs)12.1 Commercialized Drugs12.1.1 Luxturna12.1.2 Kymriah12.1.3 Provenge12.1.4 Zolgensma12.1.5 Yescarta12.1.6 Strimvelis13 Global Cell and Gene Therapy Drug Delivery Devices Market (by Region)13.1 Overview13.2 North America13.2.1 U.S.13.2.1.1 Approved Products13.2.1.2 Market Size and Forecast13.2.1.3 Key Developments13.2.2 Canada13.2.2.1 Approved Products13.2.2.2 Market Size and Forecast13.2.2.3 Key Developments13.3 Europe13.3.1 Germany13.3.1.1 Approved Products13.3.1.2 Market Size and Forecast13.3.1.3 Key Developments13.3.2 France13.3.2.1 Approved Products13.3.2.2 Market Size and Forecast13.3.2.3 Key Developments13.3.3 U.K.13.3.3.1 Approved Products13.3.3.2 Market Size and Forecast13.3.4 Italy13.3.4.1 Approved Products13.3.4.2 Market Size and Forecast13.3.4.3 Key Developments13.3.5 Spain13.3.5.1 Approved Products13.3.5.2 Market Size and Forecast13.3.5.3 Key Developments13.3.6 Netherlands13.3.6.1 Approved Products13.3.6.2 Market Size and Forecast13.3.6.3 Key Developments13.3.7 Russia13.3.7.1 Approved Products13.3.7.2 Market Size and Forecast13.3.8 Rest-of-Europe13.3.8.1 Market Size and Forecast13.3.8.2 Key Developments13.4 Asia-Pacific13.4.1 Japan13.4.1.1 Approved Products13.4.1.2 Market Size and Forecast13.4.1.3 Key Developments13.4.2 China13.4.2.1 Approved Products13.4.2.2 Market Size and Forecast13.4.2.3 Key Developments13.4.3 Australia13.4.3.1 Approved Products13.4.3.2 Market Size and Forecast13.4.3.3 Key Developments13.4.4 South Korea13.4.4.1 Approved Products13.4.4.2 Market Size and Forecast13.4.4.3 Key Developments13.4.5 India13.4.5.1 Approved Products13.4.6 Singapore13.4.6.1 Market Size and Forecast13.4.6.2 Key Developments13.4.7 Rest-of-Asia-Pacific13.4.7.1 Market Size and Forecast13.4.7.2 Key Developments13.5 Latin America13.5.1 Brazil13.5.1.1 Market Size and Forecast13.5.2 Mexico13.5.2.1 Market Size and Forecast13.5.3 Rest-of-Latin America13.5.3.1 Market Size and Forecast13.6 Rest-of-World13.6.1 Market Size and Forecast14 Competitive Landscape14.1 Key Developments and Strategies14.1.1 Overview14.1.2 Regulatory and Legal Developments14.1.3 Synergistic Activities14.1.4 M&A Activities14.1.5 Funding Activities14.2 Market Share Analysis15 Company Profiles15.1 Overview15.2 Amgen Inc.15.2.1 Company Overview15.2.2 Role of Amgen Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market15.2.3 Financials15.2.4 R&D Expenditure, 2017-201915.2.5 SWOT Analysis15.3 Bausch & Lomb Incorporated.15.3.1 Company Overview15.3.2 Role of Bausch & Lomb Incorporated., in the Global Cell and Gene Therapy Drug Delivery Devices Market15.3.3 Financials15.3.4 Key Insights About Financial Health of the Company15.3.5 SWOT Analysis15.4 Becton, Dickinson and Company15.4.1 Company Overview15.4.2 Role of Becton, Dickinson and Company in the Global Cell and Gene Therapy Drug Delivery Devices Market15.4.3 Financials15.4.4 Key Insights About Financial Health of the Company15.4.5 SWOT Analysis15.5 Bluebird bio, Inc.15.5.1 Company Overview15.5.2 Role of Bluebird bio, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market15.5.3 Financials15.5.4 R&D Expenditure, 2017-201915.5.5 SWOT Analysis15.6 Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)15.6.1 Company Overview15.6.2 Role of Castle Creek Biosciences, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market15.6.3 Key Insights About Financial Health of the Company15.6.4 SWOT Analysis15.7 Dendreon Pharmaceuticals LLC.15.7.1 Company Overview15.7.2 Role of Dendreon Pharmaceuticals LLC. in the Global Cell and Gene Therapy Drug Delivery Devices Market15.7.3 SWOT Analysis15.8 Helixmith Co., Ltd (ViroMed Co., Ltd)15.8.1 Company Overview15.8.2 Role of Helixmith Co., Ltd. in the Global Cell and Gene Therapy Drug Delivery Devices Market15.8.3 Financials15.8.4 SWOT Analysis15.9 Human Stem Cells Institute15.9.1 Company Overview15.9.2 Role of Human Stem Cell Institute in Global Cell and Gene Therapy Drug Delivery Devices Market15.9.3 SWOT Analysis15.1 Kite Pharma, Inc.15.10.1 Company Overview15.10.2 Role of Kite Pharma, Inc in Global Cell and Gene Therapy Drug Delivery Devices Market15.10.3 Financials15.10.4 R&D Expenditure, 2017-201915.10.5 SWOT Analysis15.11 Kolon TissueGene, Inc.15.11.1 Company Overview15.11.2 Role of Kolon TissueGene, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market15.11.3 SWOT Analysis15.12 Novartis AG15.12.1 Company Overview15.12.2 Role of Novartis AG in the Global Cell and Gene Therapy Drug Delivery Devices Market15.12.3 Financials15.12.4 R&D Expenditure, 2017-201915.12.5 SWOT Analysis15.13 Orchard Therapeutics plc.15.13.1 Company Overview15.13.2 Role of Orchard Therapeutics plc. in the Global Cell and Gene Therapy Drug Delivery Devices Market15.13.3 Financials15.13.4 SWOT Analysis15.14 Pfizer, Inc.15.14.1 Company Overview15.14.2 Role of Pfizer, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market15.14.3 Financials15.14.4 R&D Expenditure, 2017-201915.14.5 SWOT Analysis15.15 Renova Therapeutics15.15.1 Company Overview15.15.2 Role of Renova Therapeutics in Global Cell and Gene Therapy Drug Delivery Devices Market15.15.3 SWOT Analysis15.16 Spark Therapeutics, Inc.15.16.1 Company Overview15.16.2 Role of Spark Therapeutics, Inc. in Global Cell and Gene Therapy Drug Delivery Devices Market15.16.3 Financials15.16.4 Key Insights About Financial Health of the Company15.16.5 SWOT Analysis15.17 uniQure N.V.15.17.1 Company Overview15.17.2 Role of uniQure N.V. in Global Cell and Gene Therapy Drug Delivery Devices Market15.17.3 SWOT Analysis15.18 Vericel Corporation15.18.1 Company Overview15.18.2 Role of Vericel Corporation in the Global Cell and Gene Therapy Drug Delivery Devices Market15.18.3 Financials15.18.4 Key Insights About Financial Health of the Company15.18.5 SWOT AnalysisList of Tables Table 1: Evolution of Controlled Drug Delivery Systems: 30 Years (2000-2030)Table 5.1: Drug Delivery Methods of Cell and Gene TherapeuticsTable 5.2: Commercialized Drugs of Cell and Gene Therapy Drug Delivery Devices Market, Device Size and SpecificationTable 5.3: Comparison of Major Routes of Drug Delivery for Systemic AbsorptionTable 6.1: Ongoing Clinical Trials of Drug Delivery SystemsTable 6.2: Commercialized Drugs of Cell and Gene Therapy Drug Delivery Devices MarketTable 7.1: Pipeline Drug Delivery Devices for Cell and Gene TherapyTable 7.2: Drug Delivery Based on Lab-on-a-Chip TechnologyTable 7.3: Nanomaterials and Nanobiotechnologies used for Drug DeliveryTable 7.4: Globally Approved Lipid Nanoparticles TherapiesTable 8.1: Commercialized Cell and Gene Therapies in the MarketTable 8.2: Filing Requirements for Pre-Filled SyringesTable 8.3: Differentiation of an Injectable Therapeutic Throughout its Life CycleTable 9.1: European Commission Medical Device DirectivesTable 9.2: Federal Agencies of EU Member StatesTable 9.3: Key Market Access Landscape (9 Countries), January 2019Table 9.4: Average Selling Price of Cell and Gene Therapy Drug Delivery Devices, (2019 and 2030)Table 10.1: Patents for Cell and Gene Therapy Drug Delivery DevicesTable 13.1: List of Cell and Gene Therapy Products with Marketing Authorization in the European Union by EMAList of Figures Figure 1: Global Geriatric Population by AgeFigure 2: Global Cell and Gene Therapy Drug Delivery Devices Market SnapshotFigure 3: Dominant Segments of the Global Cell and Gene Therapy Drug Delivery Devices Market, 2019 and 2030Figure 4: Global Cell and Gene Therapy Drug Delivery Devices Market (by Product Type), 2019 and 2030Figure 5: Global Cell and Gene Therapy Drug Delivery Devices Market (by Region), 2019 and 2030Figure 6: Global Cell and Gene Therapy Drug Delivery Devices: Impact AnalysisFigure 7: Leading Players in Global Cell and Gene Therapy Drug Delivery Devices MarketFigure 2.1: Global Cell and Gene Therapy Drug Delivery Devices Market SegmentationFigure 4.1: Global Cell and Gene Therapy Drug Delivery Devices Market MethodologyFigure 4.2: Primary Research MethodologyFigure 4.3: Bottom-Up Approach (Segment-Wise Analysis)Figure 4.4: Top-Down Approach (Segment-Wise Analysis)Figure 5.1: Clinical Trials by Therapeutic Category, Cell and Gene Therapy, 2018Figure 6.1: Global Cell and Gene Therapy Drug Delivery Devices Market, $Thousand, 2019 and 2030Figure 6.2: Cell and Gene Therapy Clinical Trials (by Phase)Figure 6.3: Global Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 6.4: Cell and Gene Therapy Drug Delivery Devices Market (by Commercialized Products) 2019Figure 6.5: Cell and Gene Therapy Drug Delivery Devices Market (by Commercialized Products), 2030Figure 6.6: Most Impacted Practices in Cell and Gene Therapy Drug Delivery Devices MarketFigure 6.7: Impact of COVID-19 on Cell and Gene Therapy Drug Delivery Devices MarketFigure 6.8: Major Areas of DisruptionFigure 6.9: Impact of COVID-19 on Clinical TrialsFigure 6.10: Status of Clinical Trials (April 2020–July 2020)Figure 6.11: Disrupted Clinical Trials (by Phase of Clinical Trial)Figure 6.12: Disrupted Clinical Trials (by Therapy Area)Figure 7.1: Interrelationship of Drug Delivery Devices, Pharmaceutical Industry, and BiotechnologyFigure 8.1: Global Cell and Gene Therapy Drug Delivery Devices: Impact AnalysisFigure 8.2: Total Burden of Diseases (by Cause), 2017Figure 8.3: Number of Active and Completed Clinical Trials for Cell and Gene Therapy, 2014-2018Figure 8.4: Total Percutaneous Injuries Reported by Drug Delivery DeviceFigure 9.1: Risk Assessment of Medical DevicesFigure 9.2: FDA Regulatory Pathway for Medical DeviceFigure 9.3: FDA Regulations Modification: Pre-COVID-19 Phase to Post-COVID-19 PhaseFigure 9.4: EU Regulatory Pathway for Medical DeviceFigure 9.5: European Commission Regulations Modification: Pre-COVID-19 Phase to Post-COVID-19 PhaseFigure 9.6: Regulatory and Market Access Challenges in Asia-PacificFigure 9.7: Regulatory Environment for Medical Devices in ChinaFigure 9.8: Chinese Medical Device Classification and Pre-Market RequirementFigure 10.1: Share of Patents (by Ownership), 2016-2019Figure 11.1: Revenue Contribution of Different Segments, 2020 and 2030Figure 11.2: Subretinal Injection Cannula (by Volume), 2019-2030Figure 11.3: Subretinal Injection Cannula (by Value), 2019-2030Figure 11.4: Extension Tube (by Volume), 2019-2030Figure 11.5: Extension Tube (by Value), 2019-2030Figure 11.6: Intravenous Catheter (by Volume), 2019-2030Figure 11.7: Intravenous Catheter (by Value), 2019-2030Figure 11.8: Revenue Contribution of Sterile Insulin Syringe Segments, 2019 and 2030Figure 11.9: Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle) (by Volume), 2019-2030Figure 11.10: Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle) (by Value), 2019-2030Figure 11.11: Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle) (by Volume), 2019-2030Figure 11.12: Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle) (by Value), 2019-2030Figure 11.13: Revenue Contribution of Pre-Filled Syringe Segments, 2019 and 2030Figure 11.14: Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle) (by Volume), 2019-2030Figure 11.15: Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle) (by Value), 2019-2030Figure 11.16: Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle) (by Volume), 2019-2030Figure 11.17: Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle) (by Value), 2019-2030Figure 11.18: Revenue Contribution of Infusion Bag Segments, 2019 and 2030Figure 11.19: Infusion Bag (Size 10 ML to 50 ML) (by Volume), 2019-2030Figure 11.20: Infusion Bag (Size 10 ML to 50 ML) (by Value), 2019-2030Figure 11.21: Infusion Bag (68 ML) (by Volume), 2019-2030Figure 11.22: Infusion Bag (68 ML) (by Value), 2019-2030Figure 11.23: Infusion Bag (60 ML) (by Volume), 2019-2030Figure 11.24: Infusion Bag (60 ML) (by Value), 2019-2030Figure 11.25: Infusion Bag (Size Up to 65 ML) (by Volume), 2019-2030Figure 11.26: Infusion Bag (Size Up to 65 ML) (by Value), 2019-2030Figure 12.1: Luxturna Drug Delivery Devices (by Volume), 2019 and 2030Figure 12.2: Luxturna Drug Delivery Devices (by Value), 2019 and 2030Figure 12.3: Kymriah Drug Delivery Devices (by Volume), 2019 and 2030Figure 12.4: Kymriah Drug Delivery Devices (by Value), 2019 and 2030Figure 12.5: Provenge Drug Delivery Devices (by Volume), 2019 and 2030Figure 12.6: Provenge Drug Delivery Devices (by Value), 2019 and 2030Figure 12.7: Zolgensma Drug Delivery Devices (by Volume), 2019 and 2030Figure 12.8: Zolgensma Drug Delivery Devices (by Value), 2019 and 2030Figure 12.9: Yescarta Drug Delivery Devices (by Volume), 2019 and 2030Figure 12.10: Yescarta Drug Delivery Devices (by Value), 2019 and 2030Figure 12.11: Strimvelis Drug Delivery Devices (by Volume), 2019 and 2030Figure 12.12: Strimvelis Drug Delivery Devices (by Value), 2019 and 2030Figure 13.1: Global Cell and Gene Therapy Drug Delivery Devices Market (by Region)Figure 13.2: Global Cell and Gene Therapy Drug Delivery Devices Market (by Region), 2019 and 2030Figure 13.3: North America Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.4: North America: Market DynamicsFigure 13.5: U.S. Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.6: Projections of the Older Adult Population in the U.S.: 2016 to 2060 (Thousand)Figure 13.7: Canada Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.8: Europe Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.9: Europe-Market DynamicsFigure 13.10: Germany Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.11: France Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.12: U.K. Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.13: Italy Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.14: Spain Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.15: Netherlands Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.16: Russia Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.17: Rest-of-Europe Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.18: Europe Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.19: Asia-Pacific: Market DynamicsFigure 13.20: Japan Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.21: China Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.22: Australia Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.23: South Korea Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.24: Singapore Cell and Gene Therapy Drug Delivery Devices Market, 2020-2030Figure 13.25: Rest-of-Asia-Pacific Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.26: Latin America Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.27: Latin America: Market DynamicsFigure 13.28: Brazil Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.29: Mexico Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.30: Rest-of-Latin America Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030Figure 13.31: Rest-of-World Cell and Gene Therapy Drug Delivery Devices Market, 2020-2030Figure 14.1: Share of Key Developments and Strategies, January 2016-January 2021Figure 14.2: Regulatory and Legal Developments Share (by Company), January 2016-January 2021Figure 14.3: Synergistic Activities (by Company), January 2016-January 2021Figure 14.4: Company Share (by Synergistic Activity), January 2016-January 2021Figure 14.5: M&A Activities Share (by Company), January 2016-January 2021Figure 14.6: Funding Activities (by Company), January 2016-January 2021Figure 14.7: Market Share Analysis for the Global Cell Therapy and Gene Drug Delivery Devices Market, 2019Figure 15.1: Total Number of Companies ProfiledFigure 15.2: Amgen Inc.: Overall Product PortfolioFigure 15.3: Amgen Inc.: Pipeline Product PortfolioFigure 15.4: Amgen, Inc.: Overall Financials, 2017-2019Figure 15.5: Amgen, Inc.: Sales (by Product), 2017-2019Figure 15.6: Amgen, Inc.: Revenue (by Region), 2017-2019Figure 15.7: Amgen, Inc.: R&D Expenditure, 2017-2019Figure 15.8: Amgen Inc.: SWOT AnalysisFigure 15.9: Product Portfolio: Bausch & Lomb Incorporated.,Figure 15.10: Bausch & Lomb Incorporated.: Overall Financials, 2017-2019Figure 15.11: Bausch & Lomb Incorporated.: R&D Expenditure, 2017-2019Figure 15.12: Bausch & Lomb Incorporated.: SWOT AnalysisFigure 15.13: Becton, Dickinson and Company: Overall Financials, 2017-2019Figure 15.14: Becton, Dickinson and Company: Revenue (by Segment), 2017-2019Figure 15.15: Becton, Dickinson and Company: Revenue Split for BD Life Sciences, 2017-2019Figure 15.16: Becton, Dickinson and Company: Revenue (by Region), 2017-2019Figure 15.17: Becton, Dickinson and Company: R&D Expenditure, 2017-2019Figure 15.19: Pipeline Product Portfolio: Bluebird Bio, Inc.Figure 15.20: Bluebird Bio Inc: Overall Financials, 2017-2019Figure 15.21: Bluebird Bio Inc: R&D Expenditure, 2017-2019Figure 15.22: bluebird bio, Inc.: SWOT AnalysisFigure 15.23: Castle Creek Biosciences, Inc.: Overall Product PortfolioFigure 15.24: Castle Creek Biosciences, Inc.: Pipeline Product PortfolioFigure 15.25: Castle Creek Biosciences, Inc.: R&D Expenditure, 2017-2018Figure 15.26: Castle Creek Biosciences, Inc.: SWOT AnalysisFigure 15.27: Dendreon Pharmaceuticals LLC: Product PortfolioFigure 15.28: Dendreon Pharmaceuticals LLC.: SWOT AnalysisFigure 15.29: Helixmith Co., Ltd.: Pipeline Product PortfolioFigure 15.30: ViroMed Co: Overall Financials, 2016-2018Figure 15.31: Helixmith Co., Ltd.: SWOT AnalysisFigure 15.32: Human Stem Cell Institute: Overall Product PortfolioFigure 15.33: Human Stem Cell Institute: SWOT AnalysisFigure 15.34: Kite Pharma, Inc: Overall Product PortfolioFigure 15.35: Kite Pharma, Inc.: Pipeline Product PortfolioFigure 15.36: Kite Pharma, Inc: Overall Financials, 2017-2019Figure 15.37: Kite Pharma, Inc: Revenue (by Segment), 2017-2019Figure 15.38: Kite Pharma, Inc: Revenue (by Region), 2017-2019Figure 15.39: Kite Pharma, Inc: R&D Expenditure, 2017-2019Figure 15.40: Kite Pharma, Inc.: SWOT AnalysisFigure 15.41: Kolon TissueGene, Inc.: Pipeline Product PortfolioFigure 15.42: Kolon TissueGene, Inc.: SWOT AnalysisFigure 15.43: Novartis AG: Overall Product PortfolioFigure 15.44: Novartis AG: Pipeline Product PortfolioFigure 15.45: Novartis AG: Overall Financials, 2017-2019Figure 15.46: Novartis AG Net Revenue (by Business Segment), 2017-2019Figure 15.47: Novartis AG: Net Revenue (by Region), 2017-2019Figure 15.48: Novartis AG: R&D Expense, 2017-2019Figure 15.49: Novartis AG: SWOT AnalysisFigure 15.50: Orchard Therapeutics plc.: Pipeline Product PortfolioFigure 15.51: Orchard Therapeutics plc.: Overall Financials, 2016-2018Figure 15.52: Orchard Therapeutics plc: SWOT AnalysisFigure 15.53: Pfizer, Inc.: Pipeline Product PortfolioFigure 15.54: Pfizer Inc.: Overall Financials, 2017-2019Figure 15.55: Pfizer Inc.: Revenue (by Segment), 2017-2019Figure 15.56: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019Figure 15.57: Pfizer Inc.: Revenue (by Region), 2017-2019Figure 15.58: Pfizer Inc: R&D Expenditure, 2017-2019Figure 15.59: Pfizer, Inc.: SWOT AnalysisFigure 15.60: Renova Therapeutics: Pipeline Product PortfolioFigure 15.61: Renova Therapeutics: SWOT AnalysisFigure 15.62: Spark Therapeutics, Inc.: Overall Product PortfolioFigure 15.63: Spark Therapeutics, Inc.: Pipeline Product PortfolioFigure 15.64: Spark Therapeutics, Inc.: Overall Financials, 2015-2017Figure 15.65: Spark Therapeutics, Inc.: R&D Expenditure, 2015-2017Figure 15.66: Spark Therapeutics, Inc.: SWOT AnalysisFigure 15.67: uniQure N.V.: Pipeline Product PortfolioFigure 15.68: uniQure N.V.: SWOT AnalysisFigure 15.69: Vericel Corporation: Overall Product PortfolioFigure 15.70: Vericel Corporation: Pipeline Product PortfolioFigure 15.71: Vericel Corporation: Overall Financials, 2016-2018Figure 15.72: Vericel Corporation: Revenue (by Product), 2016-2018Figure 15.73: Vericel Corporation: R&D Expenditure (2016-2018)Figure 15.74: Vericel Corporation: SWOT Analysis